weight loss plateau management glp-1 medications The New Meds Overcome a Weight Loss Plateau:

Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations

2012;7(6):e38721

38, S63S67

Current estimates suggest: Approximately 900,000 people living with dementia in the UK (Alzheimer's Society) Two-thirds of these have Alzheimer's disease (approximately 600,000 people) Projected to rise to 1.6 million by 2040 as the population ages Healthcare and social care costs exceed 26 billion annually Informal caregiving burden is enormous, affecting family members' employment and wellbeing This disease burden explains why the NHS and research community continue pursuing disease-modifying treatments, despite repeated setbacks like the LIFT-AD trial failure

Here is where the gap between scientific proof and bold claims becomes the most apparent